Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

NCT00617344 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Fever
Dengue Hemorrhagic Fever
Dengue Virus

Interventions

BIOLOGICAL: Tetravalent CYD Dengue Vaccine , 5555 formulation
BIOLOGICAL: Tetravalent CYD Dengue Vaccine , 5553 formulation
BIOLOGICAL: Tetravalent CYD Dengue Vaccine, 4444 formulation

Sponsor

Sanofi